News Release

PET imaging of inflammation predicts recovery, guides therapy after heart attack

Peer-Reviewed Publication

Society of Nuclear Medicine and Molecular Imaging

Example of 68-year-old male patient with anterior ST-segment elevation myocardial infarction and subsequent revascularization.

image: 

Figure 3: Example of 68-year-old male patient with anterior ST-segment elevation myocardial infarction and subsequent revascularization. Molecular imaging results are given as short axis and polar map. Extent of LGE decreased from baseline to follow-up (short axis). CXCR4 PET signal slightly exceeded perfusion defect and baseline LGE extent as indicated by dotted lines.

view more 

Credit: Image created by Johanna Diekmann, MD, senior physician at the Department of Nuclear Medicine, Hannover Medical School, Germany.

Reston, VA (October 21, 2025)--A new approach to PET imaging offers a promising way for physicians to promptly identify patients who are at risk for poor functional recovery after a heart attack, according to new research published in The Journal of Nuclear Medicine. By visualizing CXCR4--a cellular protein that plays key role in inflammation--this technique can enable the timely implementation of treatments to mitigate inflammation and prevent heart failure progression.

Heart attack, also known as acute myocardial infarction (AMI), is a major cause of cardiovascular death. According to the Centers for Disease Control and Prevention, more than 800,000 Americans have a heart attack each year. After a heart attack, patients may develop progressive heart failure. Reliable tools to determine which patients will functionally recover and which patients will experience future heart issues, however, are lacking.

"We know that AMI triggers an inflammatory response in the heart, which is a determinant of subsequent healing," noted Johanna Diekmann, MD, senior physician at the Department of Nuclear Medicine, Hannover Medical School, Germany. "Our study sought to image this inflammatory response to gain spatial and functional information that could predict outcomes and better inform treatment strategies."

Researchers speculated that CXCR4 upregulation early after AMI would predict left ventricular remodeling in the heart as well as cardiac structural functional outcome. To test this hypothesis, they performed comprehensive multimodal evaluations with CXCR4-targeted PET/CT, myocardial perfusion imaging (MPI), and cardiac MRI on 49 patients within the first week after AMI. Follow-up cardiac MRI was also acquired approximately eight months after AMI in 40 of the patients.

The integrative approach demonstrated that CXCR4 upregulation extends beyond the infarct core, involves the border zone, and correlates with subsequent left ventricular dysfunction. These findings offer mechanistic insight into the link between post-ischemic inflammation and remodeling and underscores the clinical relevance of inflammatory activity after AMI.

"Conventional imaging modalities, including MPI and cardiac MR, predominantly quantify the extent of irreversible tissue damage but do not capture the dynamic inflammatory response that governs healing," noted Diekmann. "By including CXCR4-targeted PET, we can identify patients who exhibit excessive or prolonged inflammation which may predispose them to adverse remodeling and heart failure. Such information could, in the future, support risk stratification and guide emerging anti-inflammatory or reparative therapies in a precision medicine framework."

"What's more," she continued, "this approach may ultimately facilitate image-guided therapeutic strategies, allowing nuclear medicine to play an active role in monitoring and optimizing interventions that modulate inflammation, repair, and regeneration after cardiac injury."

The authors of "CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction" include Johanna Diekmann, Annika Hess, Tobias L. Ross, James T. Thackeray, and Frank M. Bengel, Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany, and Tobias Konig, Carolin Zwadlo, Andreas Schafer, and Johann Bauersachs, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.

About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world's leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics--precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit 
www.snmmi.org.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.